Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (26910)	12/15/1998 2:04:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

LGND's approach to asthma has been briefly described: Message 3416750 LGND targets STATs that control IL-4 expression. IL-4 is one of the first cytokines released by mast cells. The AXPH-Bayer tryptase inhibitor targets a serine protease which is also released by mast cells. LGND targets one of the involved proteins (IL-4) by shutting down its production, while AXPH targets another protein, by inhibiting the enzymatic activity. To get a feel for other biotechs targeting asthma, go to biocognizance.com and search for asthma. Although the site is far from complete, it will show some biotechs that mention asthma in their background paragraph. PS If the bouncing letters are distracting, or take too long to come in, just hit "stop" on your browser (which will stop the letters in their tracks), and then do the asthma search.